Company intelligence / Profile preview

Botanical Solution

Davis, California, United Statesbotanical-solution.com ↗

Ownership: Private
Employees: ~110
Development stage: Other

Overview

Botanical Solution has demonstrated that its proprietary tissue culture-derived QS‑21 is biochemically comparable and as immunogenic as traditional sources. Its biofungicide Quillibrium® is commercialized in Chile and Peru with expansion underway. The company is scaling up GMP-grade QS‑21 production to support global vaccine developers

Therapeutic areas: Infectious DiseasesOther
Modalities: Small molecule (saponin-based adjuvants)Biologic (botanical extracts for biofungicides)
Industry: Biotech

Partnerships

Syngenta (distribution of agricultural product)Croda International (pharma distribution/adjuvant scale-up)Collaborations with major pharmaceutical companies on vaccine development/adjuvants

Beyond the preview

Go deeper on Botanical Solution.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Botanical Solution.

Explore the full profile